Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
BI-1808 Combo Improves Efficacy vs Pembrolizumab Alone in Ovarian Cancer
2
Subcutaneous Isatuximab Regimens Show Efficacy in R/R Multiple Myeloma
3
Intravenous Olvi-Vec Yields Responses in NSCLC and SCLC Following Progression
4
FDA Receives NDA Submission for Bezuclastinib in Systemic Mastocytosis
5